# Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

> **NCT00835510** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 548 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Butenafine cream 1% manufactured by Taro
- **DRUG:** Lotrimin Ultra (butenafine) 1%
- **DRUG:** Butenafine Vehicle manufactured by Taro

## Key facts

- **NCT ID:** NCT00835510
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 548 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835510, "Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00835510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*